DUBLIN--(BUSINESS WIRE)--The "Cystic Fibrosis Transmembrane Conductance Regulators (CFTR) - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.The report ...

Cystic fibrosis transmembrane conductance regulator (CFTR) is a chloride channel protein, and mutations of its gene cause cystic fibrosis. CFTR is known to be expressed in epithelial cells of the ...

Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the treatment of people with cystic fibrosis. The approval is for the treatment of ...

Cystic fibrosis transmembrane conductance regulator gene rearrangements were searched by semiquantitative fluorescent multiplex polymerase chain reaction, which detected a CFTRdele2,3 (21 kb ...

Cystic fibrosis transmembrane conductance regulator (CFTR), an anion channel expressed in both epithelial and endothelial cells, regulates the organization of tight junctions between epithelial cells ...

Cystic fibrosis is caused by a genetic defect in a chloride channel called cystic fibrosis transmembrane conductase regulator. Although scientists do not fully understand how or why this defect ...

A new once daily triple drug treatment for cystic fibrosis is set to be “immediately funded” by NHS England following recommendation from the National Institute for Health and Care Excellence (NICE).1 ...

The cystic fibrosis transmembrane conductance regulator has been studied for years but the new efforts have yielded important insights. Scientists at St. Jude Children's Research Hospital and ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...

Here's what cystic fibrosis is, what causes it and how it's usually treated once it has been diagnosed. Start the day smarter. Get all the news you need in your inbox each morning. What is ...

The FDA has expanded the indication for Kalydeco® (ivacaftor) to include treatment of cystic fibrosis in patients 4 months to less than 6 months of age. Menu SECTIONS. Home; Drug Monographs.